Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

T2N0 º´±â ¼º¹®¾ÏÀÇ ¹æ»ç¼±Ä¡·á Radiation Therapy for T2N0 Glottic Cancer

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2006³â 24±Ç 4È£ p.217 ~ 222
±èÀçö,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÀçö ( Kim Jae-Chul ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç

Abstract

¸ñ Àû: T2N0 º´±â ¼º¹®¾Ï ȯÀÚ¿¡¼­ ¹æ»ç¼±Ä¡·áÀÇ °á°ú ¹× ¹«º´»ýÁ¸À²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿¹ÈÄÀÎÀÚ¸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 1986³â 9¿ùºÎÅÍ 2004³â 6¿ù±îÁö º»¿ø¿¡¼­ ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº 30¿¹ÀÇ T2N0 º´±â ¼º¹®¾Ï ȯÀÚ¸¦ ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. ´ë»ó ȯÀÚ ¸ðµÎ ³²ÀÚ¿´À¸¸ç ¿¬·É ¹üÀ§´Â 39¼¼¿¡¼­ 79¼¼¿´´Ù(Áß°£°ª 62¼¼). Á¶Á÷ÇÐÀû À¯ÇüÀº 30¿¹ ¸ðµÎ ÆíÆò»óÇǼ¼Æ÷¾ÏÀ̾ú´Ù. ¹æ»ç¼±Ä¡·á´Â 6 MV ¼±Çü°¡¼Ó±â¸¦ ÀÌ¿ëÇÏ¿´°í, Èĵο¡ Á¶»çµÈÃѹæ»ç¼±·®Àº 66¡­70 GyÀÇ ¹üÀ§¿´´Ù(Áß°£°ª 66 Gy). ÃßÀû±â°£ÀÇ Áß°£°ªÀº 63°³¿ùÀ̾ú´Ù.

°á °ú: ´ë»ó ȯÀÚ ÀüüÀÇ 5³â ¹«º´»ýÁ¸À²Àº 79%¿´´Ù. ¼º¹®ÇÏ Ä§¹üÀÌ Àִ ȯÀÚ¿¡¼­´Â 5³â ¹«º´»ýÁ¸À²ÀÌ °¨¼ÒÇÏ´Â ¾ç»óÀ» º¸¿´´Ù(p£¼0.05). Àü¿¬ÇÕ Ä§¹ü, ¼º¹®»ó ħ¹ü, ¼º¹® ¿îµ¿¼º °¨¼Ò µîÀº 5³â ¹«º´»ýÁ¸À²ÀÇ °¨¼Ò¿Í¹«°üÇÏ¿´´Ù. µ¿½Ã È­Çпä¹ý Ãß°¡ ¶ÇÇÑ Åë°èÀû ÀÇÀÇ°¡ ¾ø¾ú´Ù. ¿ø¹ßº´¼Ò Àç¹ß 3¿¹ ¹× °æºÎ¸²ÇÁÀý Àç¹ß 2¿¹´Â ±ÙÄ¡Àû ¼ö¼ú·Î ±¸Á¦µÇ¾úÀ¸³ª, ¿ø¹ßº´¼Ò ¹× ¸²ÇÁÀý µ¿½ÃÀç¹ß 2¿¹´Â ±ÙÄ¡Àû ¼ö¼ú·Î ±¸Á¦µÇÁö ¸øÇÏ¿´´Ù. ÃÖÁ¾±¹¼ÒÁ¦¾îÀ²Àº 86%¿´°í, ¼º´ë º¸Á¸À²Àº 83%¿´´Ù.

°á ·Ð: T2N0 ¼º¹®¾Ï¿¡¼­ ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á ½Ã ¼º¹®ÇÏ Ä§¹üÀÌ ¹«º´»ýÁ¸À²¿¡ ¿µÇâÀ» ÁÙ ¼ö ÀÖ´Â ÀÎÀÚ·Î ºÐ¼®µÇ¾ú´Ù.

Purpose: This study evaluated the results of definitive radiation therapy and the prognostic factors that
affect survival rates for T2N0 glottic cancer patients.

Materials and Methods: Thirty patients with T2N0 glottic cancer who were treated with definitive radiation
therapy at our institution between September 1986 and June 2004 were retrospectively reviewed. All patients
were pathologically confirmed as having squamous cell carcinoma and were staged as AJCC T2N0. The
age of the patients ranged from 39 to 79 (median 62) years and all were male. A total dose of 66¡­70 Gy
(median 66 Gy) was delivered with a 6-MV linear accelerator in 6.5¡­7 weeks. The median follow-up period
was 63 months.

Results: The actuarial disease-free survival rate for the entire group of the patients was 79% at 5 years.
The five-year disease-free survival rates for patients without and with subglottic extension were 90% and
56%, respectively (p=0.03). However, anterior commissure involvement, supraglottic extension, and impaired
cord mobility were not statistically significant prognostic factors. The five-year disease-free survival rates for
patients with and without concurrent chemotherapy were 86% and 69%, respectively (p=0.47).

Conclusion: Subglottic extension can be considered a poor prognostic factor for T2N0 glottic cancer.

Å°¿öµå

¼º¹®¾Ï;¹æ»ç¼±Ä¡·á
Glottic cancer;Radiation therapy

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS